44th week of 2012 patent applcation highlights part 38 |
Patent application number | Title | Published |
20120276127 | TREATMENT OF RETINAL DISORDERS WITH RECOMBINANT T CELL RECEPTOR LIGAND (RTL) - Methods are provided for the treatment of a retinal disorder or optic neuritis in a subject. In some embodiments, the methods include administering a therapeutically effective amount of an MHC molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an MHC class I α1 domain and the second domain is an MHC class I α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises a retinal antigen or an antigen of the central or peripheral nervous system. | 2012-11-01 |
20120276128 | HIV Envelope-CD4 Complexes and Hybrids - Env-CD4 polypeptide complexes and hybrids that expose cryptic epitopes important in virus neutralization are disclosed. Methods of diagnosis, treatment and prevention using the polypeptides are also provided. | 2012-11-01 |
20120276129 | NEISSERIAL ANTIGENIC PEPTIDES - This invention provides, among other things, proteins, polypeptides, and fragments thereof, derived from the bacteria | 2012-11-01 |
20120276130 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR RHEUMATIC HEART DISEASE BASED UPON GROUP A STREPTOCOCCUS MARKERS - This invention is in the field of identifying patients having rheumatic heart disease (RHD) associated with | 2012-11-01 |
20120276131 | ANTI-TRYPANOSOMIASIS VACCINES AND DIAGNOSTICS - The present invention has as an object a novel genetic material coding for trans-sialidase-like proteins of African trypanosomes, and relates to the use of said genes and proteins in vaccines, therapeutics and diagnostics. The present invention also relates to the immunization of human and/or nonhuman animals against trypanosomosis. | 2012-11-01 |
20120276132 | Atoxic recombinant holotoxins of Clostridium difficile as immunogens | 2012-11-01 |
20120276133 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR INDUCING REGULATORY B CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and/or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells. | 2012-11-01 |
20120276134 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ANTIGEN-SPECIFIC DELETION OF T EFFECTOR CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering immunosuppressants and MHC Class I-restricted and/or MHC Class II-restricted epitopes that can generate tolerogenic immune responses (e.g., antigen-specific T effector cell deletion). | 2012-11-01 |
20120276135 | METHODS FOR IMPROVING THE DESIGN, BIOAVAILABILITY, AND EFFICACY OF RANDOM SEQUENCE POLYMER COMPOSITIONS VIA SERUM PROTEIN-BASED DETECTION OF RANDOM SEQUENCE POLYMER COMPOSITIONS - There exist in the art methods of detecting simple peptides. However, methods to determine the effective plasma concentration of mixtures of peptides as a group, rather than for individual peptides with a defined amino acid sequence, are complicated by the heterogeneity of the peptides to be detected. This application provides improved methods of detecting and assessing random sequence polymer (RSP) compositions, methods for the detection and quantitation of RSP compositions, means to determine and enrich a subset of peptides in an RSP composition based on the subset's interactions with certain capture polypeptides, and methods for administering RSP compositions to a subject in need thereof, wherein the dosage regimen and quantity may be determined or evaluated based on the above-mentioned methods for detection and quantitation. | 2012-11-01 |
20120276136 | CHEMICALLY PROGRAMMABLE IMMUNITY - The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule. | 2012-11-01 |
20120276137 | COMPOSITIONS AND METHODS FOR PREPARING STAPHYLOCOCCUS AUREUS SEROTYPE 5 AND 8 CAPSULAR POLYSACCHARIDE CONJUGATE IMMUNOGENIC COMPOSITIONS - The present invention relates to immunogenic conjugates comprising | 2012-11-01 |
20120276138 | RAPID AND PROLONGED IMMUNOLOGIC-THERAPEUTIC - The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT). | 2012-11-01 |
20120276139 | USE OF NEWCASTLE DISEASE VIRUS-BASED VECTOR FOR INDUCING AN IMMUNE RESPONSE IN MAMMALS - The invention relates to methods of stimulating an immune response against an antigenic protein in a mammalian subject. More specifically, the invention relates to routes of administration of a hybrid Newcastle Disease Virus-vector (NDV-vector) for eliciting an immune response against an antigenic protein that is encoded by the hybrid NDV-vector. | 2012-11-01 |
20120276140 | COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND ALLERGIC IMMUNITY - Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma). | 2012-11-01 |
20120276141 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE - Provided herein are small molecule CD4 mimetics effective to bind to HIV Env proteins. A CD4 mimetic of the invention, when bound to an Env protein, is effective to induce a conformational change in the Env protein such that cyptic epitopes on the Env protein are exposed. Also provided herein are related methods of identifying and using such small molecule CD4 mimetics, for example, to elicit an immune response in a subject upon administration. | 2012-11-01 |
20120276142 | NUCLEIC ACID SEQUENCES ENCODING AND COMPOSITIONS COMPRISING IGE SIGNAL PEPTIDE AND/OR IL-15 AND METHODS FOR USING THE SAME - Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors are disclosed as well as recombinant vaccines and live attenuated pathogens encoding fusion proteins, and methods of using the same, are disclosed. The immunomodulatory effect following delivery of IL-15 and CD40L, with or without immunogens, is disclosed as are various nucleic acid molecules and compositions thereof used for delivering such proteins and methods of using such compositions. | 2012-11-01 |
20120276143 | PROBIOTIC BIFIDOBACTERIUM STRAIN | 2012-11-01 |
20120276144 | Pro-Apoptotic Bacterial Vaccines To Enhance Cellular Immune Responses - Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected. | 2012-11-01 |
20120276145 | EXTRACELLULAR MATRIX PROTEINS FROM HAEMOPHILUS INFLUENZAE BIOFILMS: TARGETS FOR THERAPEUTIC OR DIAGNOSTIC USE - A method of identifying a biofilm that includes non-typeable | 2012-11-01 |
20120276146 | VACCINE AGAINST CHOLERA AND ENTEROTOXIGENIC E. COLI (ETEC) DIARRHEA - A vaccine against cholera and/or ETEC is provided, comprising a | 2012-11-01 |
20120276147 | CTSP CANCER-TESTIS ANTIGENS - The invention relates to CTSP polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigen, CTSP-1. | 2012-11-01 |
20120276148 | ADENOVIRAL VECTOR VACCINE - Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term. | 2012-11-01 |
20120276149 | METHODS FOR MODULATING BACTERIAL INFECTION - The present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria. More particularly, the present invention relates to methods for treating or reducing the risk of or preventing diseases caused by or associated with pathogenic bacteria of the gastrointestinal (GI) tract. The present invention further relates to methods for promoting pathways induced by commensal bacteria of the GI tract that lead to Th17 differentiation, which in turn leads to localized and systemic accumulation of Th17 cells. Compositions and medicaments are also described herein that are used alleviate and/or prevent symptoms associated with diseases caused by or associated with pathogenic bacteria. Accordingly, the compositions, medicaments and methods described herein may be used to address the needs of patients or subjects that would benefit from increased Th17 cell differentiation. | 2012-11-01 |
20120276150 | SOFT TISSUE WRAP - Compositions and methods for treating and healing injured soft tissues such as tendons and ligaments are provided. The composition may be a wrap comprising human collagen in the form of a sheet. The human collagen has been processed so that is retains proteins that are associated with it in its natural state. The sheet may optionally be coated on one or more sides with one or more of additional human collagen, therapeutic agents, additional soft tissue growth factors or hydroxyapatite. | 2012-11-01 |
20120276151 | DRUG DELIVERY FROM EMBOLIC AGENTS - An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 μm and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver. | 2012-11-01 |
20120276152 | SYSTEMS AND METHODS OF USING ZINC-CHELATOR TO TREAT MYOCARDIAL INFARCTION - Methods and systems for treating an infarct by delivery of zinc chelator to modulate tissue. | 2012-11-01 |
20120276153 | USE OF AEROSOLIZED LEVOFLOXACIN FOR TREATING CYSTIC FIBROSIS - Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising | 2012-11-01 |
20120276154 | CREATION OF HAIR FOLLICLES IN TISSUE-ENGINEERED SKIN GRAFTS - A living tissue-engineered skin graft having a potential to develop hair follicles includes a multilayered skin-like structure of alternating nanofiber mats and layers of fibroblasts assembled in a layer-by-layer fashion. Aggregates of dermal papilla capable of developing into hair follicles are embedded in the multilayered structure such that the aggregates develop into hair follicles upon culturing the multilayered structure. Keratinocytes are provided as an outer layer of the skin graft. Fibroblasts, keratinocytes and dermal papilla cells are isolated from skin and cultured to form suspensions of cells for fabricating the skin graft. Aggregates of dermal papilla cells are generated using a hanging drop method. Nanofiber mats are formed by electrospinning biocompatible materials onto a culture media or a layer of fibroblast suspension. The skin graft has dermal and epidermal layers and provides a biomimetic environment to promote healing and hair growth. | 2012-11-01 |
20120276155 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells. | 2012-11-01 |
20120276156 | TOLEROGENIC SYNTHETIC NANOCARRIER COMPOSITIONS WITH TRANSPLANTABLE GRAFT ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens. | 2012-11-01 |
20120276157 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen. | 2012-11-01 |
20120276158 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes. | 2012-11-01 |
20120276159 | TOLEROGENIC SYNTHETIC NANOCARRIERS - This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses. | 2012-11-01 |
20120276160 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR REGULATING INNATE IMMUNE RESPONSES - Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to reduce antigen-specific activation of innate immune cells. | 2012-11-01 |
20120276161 | BIORESORBABLE AND BIOCOMPATIBLE COMPOUNDS FOR SURGICAL USE - A bioresorbable and biocompatible compound for surgical use is composed of functionalized collagen cross-linked with a glycosaminoglycan. | 2012-11-01 |
20120276162 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 2012-11-01 |
20120276163 | ANTI-CANCER COMPOSITION COMPRISING ALGINATE - The present invention relates to a biologically acceptable composition for the prophylaxis and/or treatment of colorectal cancer comprising an iron chelator, wherein the composition is adapted for the selective targeting of the iron chelator to the colon. | 2012-11-01 |
20120276164 | IMPLANTABLE PASTE AND ITS USE - The present invention relates to an implantable paste comprising bioactive glass spheres having a size distribution of 50-425 μm, low molecular weight polyethylene glycol having a molecular weight range of 200-700 g/mol, medium molecular weight polyethylene glycol having a molecular weight range of 700-2500 g/mol and high molecular weight polyethylene glycol having a molecular weight range of 2500-8000 g/mol, with the proviso that the molecular weight of the low molecular weight polyethylene glycol and of the medium molecular weight polyethylene glycol differ from each other by at least 80 g/mol and that the molecular weight of the medium molecular weight polyethylene glycol and of the high molecular weight polyethylene glycol differ from each other by at least 300 g/mol. | 2012-11-01 |
20120276165 | MICRO-COLLOIDAL SILICIC ACID/BORIC ACID COMPOSITION AND A METHOD OF PREPARING A BIOENHANCING SOLUTION AND POWDER - The present invention provides a composition comprising an acidified aqueous solution of (1) micro colloidal silicic acid, (2) boric acid, and (3) a water absorbing additive, having a pH value of equal to or less than 1, wherein the micro colloidal silicic acid has particle sizes in the range of 1-8 nm, especially in the range of 1.5-6 nm. The invention also provides a particulate product obtainable by the method according to claim | 2012-11-01 |
20120276166 | ELUTION-STABILIZED PREPARATION - The invention provides a solid preparation which does not undergo the delay of elution of the active ingredient even after long-term storage. The solid preparation independently contains a teneligliptin-containing part containing teneligliptin or a salt thereof, or a solvate of teneligliptin or the salt thereof, in an amount 1.5- to 10-fold larger than that desired for the solid preparation. | 2012-11-01 |
20120276167 | IMMUNOPROTECTION BY ORAL ADMINISTRATION OF RECOMBINANT LACTOCOCCUS LACTIS MINI-CAPSULES - In one embodiment, the present invention provides for an edible mini-capsule form of live, non-persisting, recombinant | 2012-11-01 |
20120276168 | AMINO ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME - The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized bu chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology. | 2012-11-01 |
20120276169 | POLYMER NANOPARTICLE INJECTION FORMULATION COMPOSITION CONTAINING RAPAMYCIN WITH IMPROVED WATER SOLUBILITY, PREPARATION METHOD THEREOF, AND ANTICANCER COMPOSITION FOR COMBINED USE WITH RADIOTHERAPY - The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy. | 2012-11-01 |
20120276170 | INJECTABLE DRUG CARRIER COMPRISING LAYERED DOUBLE HYDROXIDE - Provided is an injectable drug carrier including a non-toxic Layered Double Hydroxide (LDH) and pharmaceutically acceptable excipients. Provided is also a method of preparing the injectable drug carrier, the method including: synthesizing LDH with various compositions and controlling the size and shape of the LDH at a level that the LDH has no adverse effect in vivo. A solution obtained by dispersing the LDH in a solvent is injected in vivo. According to the method, nano-size LDH that does not affect a blood vessel in vivo can be synthesized. The LDH thus synthesized has no adverse effect in vivo even at a concentration of 400 mg/kg, and thus can contribute to establishment of a drug delivery system capable of improving the delivery efficiency of a specific drug. | 2012-11-01 |
20120276171 | MICELLE ENCAPSULATION OF THERAPEUTIC AGENTS - The invention provides active agents, such as paclitaxel, rapamycin, or 17-AAG, encapsulated by safe poly(ethylene glycol)-block-poly(lactic acid) (“PEG-b-PLA”) micelles. The compositions provide effective solubilization of drug combinations, such as paclitaxel, rapamycin, and 17-AAG, as well as others described herein. A significant advantage of PEG-b-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO, which are used in currently known compositions. Additionally, PEG-b-PLA micelles are easier to handle than DMSO and they do not possess a foul odor, which is a problem with formulations currently in clinical trials. Accordingly, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. It was also found that larger doses of individual drugs in micelle formulations can be administered compared to non-micelle formulations. | 2012-11-01 |
20120276172 | POLYMERIC MATERIALS FOR MEDICAL DEVICES - The present invention includes biocompatible polymeric coatings, membranes, matrices, and films to be used with implantable medical devices. Medical devices containing such materials applied to a surface thereof contain a film-forming fluorous homo-polymer or copolymer containing the polymerized residue of a fluorous moiety, wherein the relative amounts of the polymerized residues of one or more moieties are effective to provide the coating and films with properties effective for use in coating implantable med devices. | 2012-11-01 |
20120276173 | Glycosaminoglycan Compositions in Combination with Stem Cells - A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided. | 2012-11-01 |
20120276174 | Therapeutic Treatment of Dermatologic Skin Disorders - is incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders. In particular, | 2012-11-01 |
20120276175 | Personal Cleansing Compositions with Increased Deposition of Polyacrylate Microcapsules - A personal cleansing composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair and/or skin. The personal cleansing composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier. | 2012-11-01 |
20120276176 | Method and Kit For Hair Removal - A method of removing hair from skin is provided, comprising the steps of:
| 2012-11-01 |
20120276177 | VISUALLY PATTERNED AND ORIENTED COMPOSITIONS - Structured personal care compositions comprising a particle having an aspect ratio of greater than 1.5 are contemplated, as well as methods for using such compositions. The compositions provide a visually distinguishable, oriented pattern that is aesthetically pleasant to provide consumer appeal and product identification. | 2012-11-01 |
20120276178 | AQUEOUS COSMETIC - A constitution in which at least 5 to 30% by mass of titanium oxide, an acid dye or an organic pigment, an alkali-soluble type acryl resin and water are contained is employed in order to provide aqueous cosmetics having the respective compositions in an acid dye aqueous cosmetic containing titanium oxide and an acid dye or an organic pigment aqueous cosmetic containing titanium oxide and an organic pigment which is excellent in an aging settling stability of titanium oxide to make a hard cake less liable to be produced even when titanium oxide settles down and can readily be redispersed by stirring and which is excellent in usability and a coating performance and suited to manicure compositions for a nail art, cosmetics for skin coloring and the like. | 2012-11-01 |
20120276179 | COSMETIC PRODUCT, NANOPARTICLES FOR COSMETICS, AND POWDER FOR COSMETICS - The invention provides a cosmetic product which has a good texture and allows full expression of the inherent functions of ceramide as an intercellular lipid, such as skin barrier function and hair protection effect, as well as nanoparticles for cosmetics and powder for cosmetics which may be used in the above cosmetic product, exhibit good skin barrier function and hair protection effect, and are easy to incorporate into the above cosmetic product. The cosmetic product, the nanoparticles, and the powder for cosmetics according to the present invention contain a polymer obtained by polymerization of a monomer material containing a glycerol(meth)acrylate monomer represented by the formula (1): | 2012-11-01 |
20120276180 | Active Agent Delivery and/or Odor Retentive Composition and Methods of Use Thereof - An active agent delivery and/or odor retentive composition including a surfactant and wax spheres formed from at least one of beeswax and soy wax and methods of use thereof. The composition is particularly useful in the cosmetics and medical industry for delivering/carrying a particular ingredient to one's skin, scalp or hair; for absorbing odor causing materials, such as fuel byproducts from a skin surface; and/or for providing exfoliating properties to the skin. The delivery system/carrying system is also useful in binding to certain nutritional materials, such as vitamins, minerals, antioxidants, and the like for ingestion and release into the body. | 2012-11-01 |
20120276181 | System for Reducing Bacteria on Food Surfaces While Extending Shelf Life - A synergistic system for substantially reducing surface contaminants of a food and inhibiting yeast, mold and bacteria growth in a food, beverage or food grade cosmetic preparation comprising a substantially transparent and odorless solution made from a plurality of substantially organic compounds selected from: citric acid, sodium citrate, vegetable glycerin, sea salt, potassium sorbate, decyl glucoside, calcium ascorbate, grapefruit seed extract, quillaja saponin, calcium carbonate, ascorbic acid, sodium percarbonate and sodium bisulfite, and an applicator for applying the solution to the food substance. | 2012-11-01 |
20120276182 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS - The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition. | 2012-11-01 |
20120276183 | ABSORBENT MATERIAL - An absorbent product intended particularly for use as a wound dressing comprises an admixture of carboxymethyl chitosan and chitosan wherein the chitosan incorporates at least one antimicrobial agent. Absorbency is provided by the carboxymethyl chitosan and antimicrobial properties by the antimicrobial agent incorporated in the chitosan. | 2012-11-01 |
20120276184 | SOLVENT CAST FILM SUSTAINED RELEASE LATANOPROST IMPLANT - The present invention provides a sustained release latanoprost implant in the form of a thin film comprising latanoprost incorporated in a biodegradable polymer matrix. Preferably, said implant is an intraocular implant comprising a thin film comprising latanoprost incorporated in a biodegradable polymer matrix wherein said implant is configured as a disc or a rolled film that can be inserted into the eye and unrolls to provide a film having a high surface area to volume ratio. | 2012-11-01 |
20120276185 | SOLUBLE COATING COMPRISING POLYELECTROLYTE WITH HYDROPHOBIC COUNTERIONS - The present invention provides an implantable device having a biosoluble coating comprising a polyelectrolyte and a counterion and the methods of making and using the same. | 2012-11-01 |
20120276186 | SUSTAINED RELEASE LATANOPROST IMPLANT - The present invention provides a sustained release, biodegradable intraocular latanoprost implant for reducing elevated intraocular pressure in an individual in need thereof. The implant can be configured as a film (e.g., a rolled film) or extruded filament, either of which can be inserted into the eye of the individual to provide for extended release of latanoprost for several days. Upon insertion into the eye, a rolled film may unroll to provide a film having a high surface area to volume ratio for drug diffusion. | 2012-11-01 |
20120276187 | TABLETTED CHEWING GUM SWEET - A medicated chewing gum tablet comprising at least two layers, a first layer prepared by compressing a gum base material and tablet base material, and a second layer prepared by compressing a tablet base material, wherein the second layer further comprises an active ingredient being a mineral salt, wherein the mineral is calcium. | 2012-11-01 |
20120276188 | BIOMATERIALS MADE FROM HUMAN HAIR - A hydrogel that comprises denatured human hair biomolecules intermolecularly crosslinked with disulfide bonds to form a hydrogel. The hydrogel may be prepared by reduction and denaturation of hair to provide keratins and other hair biomolecules that are crosslinked by the disulfide bonds to provide a firm, flexible, and useful biomaterial. | 2012-11-01 |
20120276189 | Therapeutic Treatment of Dermatologic Skin Disorders - β-glucans are incorporated with liposomes in therapeutic compositions for topical application to prevent or alleviate the conditions and symptoms of cosmetic and dermatologic disorders. In particular, β-glucan is combined with liposomes to increase the penetration of the β-glucan into the skin, to provide hydration of the skin during treatment. The deeper penetration of the β-glucan increases macrophage activity to remove scar tissue, dead skin cells and other foreign debris as well as stimulating collagen growth to improve skin health. | 2012-11-01 |
20120276190 | THERAPY WITH A CHIMERIC MOLECULE AND A PRO-APOPTOTIC AGENT - The present invention provides compositions comprising a chimeric molecule comprising a cytotoxin that inhibits protein synthesis and an agent that inactivates an anti-apoptotic BCL-2 family member protein and methods of inhibiting the growth of or promoting the apoptosis of an aberrantly proliferating cell population by co-administering the chimeric molecule and the agent that inactivates an anti-apoptotic BCL-2 family member protein. | 2012-11-01 |
20120276191 | Treatment and Diagnosis of Macrophage Mediated Disease - The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula | 2012-11-01 |
20120276192 | COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ICAM-1 - RNA interference using small interfering RNAs which are specific for the ICAM-1 gene inhibits expression of this gene. Diseases which involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy and other complications arising from type I diabetes, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs. | 2012-11-01 |
20120276193 | Agents, Uses and Methods - The present invention relates to therapeutic agents for the targeted delivery of an immunosuppressive agent to monocytes and/or monocyte-derived cells comprising a binding moiety with specificity for monocytes and/or monocyte-derived cells and an immunosuppressive agent. In one embodiment, the agent is a glucocorticoid-antibody conjugate. The invention also relates to methods, uses, kits and compositions comprising such agents. | 2012-11-01 |
20120276194 | PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD AND USES THEREOF - The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame see oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion. | 2012-11-01 |
20120276196 | Pharmaceutical Compositions of a Neuroactive Steroid and Methods of Use Thereof - The present invention relates to pharmaceutical compositions of the neuroactive steroid 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, with properties desirable for use in treating mood disorders and the like. The pharmaceutical compositions provide sustained therapeutic plasma levels of 3α-hydroxy-3β-methoxymethyl-21-(1′-imidazolyl)-5α-pregnan-20-one. The present invention also relates to methods of treating these disorders by administering the pharmaceutical compositions. | 2012-11-01 |
20120276197 | Dosage Form to Increase Prasterone Bioavailability - A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability. | 2012-11-01 |
20120276198 | PHARMACEUTICAL COMPOSITION FOR TREATING PARKINSON'S DISEASE AND PREPARATION METHOD THEREOF - A pharmaceutical composition used to treat Parkinson's disease contains levodopa, carbidopa and entacapone or pharmaceutically acceptable salt thereof, and at least one kind of pharmaceutically acceptable excipients. Entacapone is not mixed with levodopa or carbidopa in the pharmaceutical composition. The preparation method of the pharmaceutical composition includes making the first particles with levodopa and carbidopa, making the second particles with entacapone, and then pressing the two kinds of particles into tablets. | 2012-11-01 |
20120276199 | TASTE MASKED PHARMACEUTICAL FORMULATIONS - The present invention relates to taste masked pharmaceutical formulations, processes for preparing the same and methods of using them. The present invention relates to taste masked effervescent formulations comprising fexofenadine or a pharmaceutically acceptable salt thereof, processes for preparing the same, and therapeutic uses and methods of treatment employing such formulations. | 2012-11-01 |
20120276200 | FORMULATIONS OF QUINOLINONES - A pharmaceutical formulation, comprising: a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof, | 2012-11-01 |
20120276201 | COMPOSITIONS AND METHOD FOR TREATMENT AND PROPHYLAXIS OF INFLAMMATORY BOWEL DISEASE - Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD. | 2012-11-01 |
20120276202 | COLLAGEN MATRIX FOR TISSUE ENGINEERING - The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease. | 2012-11-01 |
20120276203 | COLLAGEN MATRIX FOR CELL THERAPY - The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease. | 2012-11-01 |
20120276204 | Bone Growth Compositions and Methods - The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur. | 2012-11-01 |
20120276205 | SILVER OXIDE FORMULATIONS - A formulation including at least one silver oxide including a silver(II) oxide, the silver(II) oxide having an irregular macrocrystal structure, the silver oxide having an average particle size (D | 2012-11-01 |
20120276206 | METHOD FOR MANUFACTURING ACID PELLETS - The invention relates to an improved method of manufacturing substantially spherical/ball-shaped tartaric acid starter pellets which are suitable for preparing active substance-containing medicament formulations, as well as the pellets as such that may be obtained in this way, and their use as starting material for the preparation of active substance-containing medicament formulations. | 2012-11-01 |
20120276207 | METHODS FOR PREPARATION OF LIPID-ENCAPSULATED THERAPEUTIC AGENTS - Fully lipid-encapsulated therapeutic agent particles of a charged therapeutic agent are prepared by combining a lipid composition containing preformed lipid vesicles, a charged therapeutic agent, and a destabilizing agent to form a mixture of preformed vesicles and therapeutic agent in a destabilizing solvent. The destabilizing solvent is effective to destabilize the membrane of the preformed lipid vesicles without disrupting the vesicles. The resulting mixture is incubated for a period of time sufficient to allow the encapsulation of the therapeutic agent within the preformed lipid vesicles. The destabilizing agent is then removed to yield fully lipid-encapsulated therapeutic agent particles. The preformed lipid vesicles comprise a charged lipid which has a charge which is opposite to the charge of the charged therapeutic agent and a modified lipid having a steric barrier moiety for control of aggregation. | 2012-11-01 |
20120276208 | ACUTE COGNITIVE AND MOOD EFFECTS OF PLANT POLYSACCHARIDES IN ADULT HUMAN SUBJECTS - Compositions and methods to improve cognitive performance and mood in an adult human subject's are presented herein. The method of the present invention involved the administration of a dietary supplement comprising plant polysaccharides. The compositions disclosed herein have beneficial effects on memory performance and tasks of high cognitive demand independent of blood glucose responses and despite mental fatigue. | 2012-11-01 |
20120276209 | NUCLEIC ACID-CONTAINING LIPID PARTICLES AND RELATED METHODS - Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles. | 2012-11-01 |
20120276210 | Shampoo Compositions with Increased Deposition of Polyacrylate Microcapsules - A shampoo composition that increases the deposition and retention of benefit agent containing polyacrylate microcapsules onto hair during the cleansing process. The shampoo composition is based on the combination of anionic charged polyacrylate microcapsules, cationic deposition polymers, detersive surfactant, and a carrier. | 2012-11-01 |
20120276211 | POLYMERIZABLE LACTAMIC COPOLYMERS SUITABLE FOR THE FORMATION OF COATINGS ON MICROENCAPSULATED PARTICLES - This present application relates to microcapsules or compositions containing microcapsules wherein the microcapsules comprise a polymerizable lactamic copolymer. More particularly, certain aspects are directed to the use of polymerizable lactamic copolymers in the formation of coatings on microencapsulated particles. These polymerizable lactamic copolymers can result in surface modified microencapsulated particles that may be anionic, non-ionic, or cationic. | 2012-11-01 |
20120276212 | COMPOSITION COMPRISING PLANT AND/OR FISH OILS AND NON-OXIDIZABLE FATTY ACID ENTITIES - The present invention concerns a composition prepared from a combination of plant oil and/or fish oil and a compound comprising non. β-oxidizable fatty acid analogues, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, secondary stenosis, myocardial infarction, stroke, elevated blood pressure, endothelial dysfunction, procoagulant state, polycystic ovary syndrome, the metabolic syndrome, cancer, inflammatory disorders and proliferate skin disorders. The present invention also concerns an animal feed prepared from a combination of plant oil and/or fish oil and a compound comprising non β-oxidizable fatty acid analogues, the use of said feed for improving the body composition of an animal, and a product produced from said animal. | 2012-11-01 |
20120276213 | METHOD FOR ENZYMATIC TREATMENT OF TISSUE PRODUCTS - Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix. | 2012-11-01 |
20120276214 | INFANT NUTRITION WITH PROTEASE INHIBITOR - Provided is an infant nutrition comprising at least one protease inhibitor, a process for preparing such an infant nutrition and use of the infant nutrition for the treatment and/or prevention of childhood obesity and secondary disorders resulting from childhood obesity. | 2012-11-01 |
20120276215 | Therapeutic Conditioned Media - Disclosed are therapeutic compositions useful for treatment of degenerative, autoimmune, inflammatory, and neurological conditions. In one embodiment, clinical conditions are treated by administration of a standardized composition of stem cell, progenitor cell, or cellular supernatant. The invention provides doses of conditioned media that mediate therapeutic effects at concentrations that would not be expected to produce biological effects. | 2012-11-01 |
20120276216 | Therapeutic Water Treatment - A therapeutic treatment process a source for generating specific frequencies that are able to provide a concentrated specific frequency to individual molecules of a fluid such as water. The specific frequency that is applied to the individual molecules has been determined to cause the molecule to “mimic” the effect of a specific substance or to cause a cell to do so. One such mechanism is the treated molecule acting as an agonist that triggers the receptor of a cell to release the function of the cell. These cell functions may mimic such substances as oxygen, amino acids, antioxidants, as well as substances that help nerves, hormones, bones, muscle, skin, hair, eyes, digestion, sleep and many more. The effects from the substances may include without limitation non-specific effects such as relaxing, energizing, calming, anti-aging and other effects that may benefit widely disparate individuals, as well as therapeutic effects for specific diseases and conditions for specific individuals. | 2012-11-01 |
20120276217 | DISINFECTING FORMULATION - The present invention provides a disinfecting formulation useful, for example, for cleaning and disinfecting human or animal body parts, and in particular for disinfecting human hands. Typically, the formulation comprises alcohol, one or more essential oils comprising cineole, gelling agent and water. The invention also provides methods of disinfection of human and animal body parts and methods for preparing the formulation. | 2012-11-01 |
20120276218 | CONTROLLING CALCIUM COMPOUND FORMATION IN BIOCOMPATIBLE MATERIALS FOR TISSUE REGENERATION AND REPAIR IN MAMMALS - A biocompatible composition for tissue repair or regeneration in mammals comprising one or more glass former compounds selected from the group consisting of B | 2012-11-01 |
20120276219 | COMPOSITIONS HAVING A HIGH ANTIVIRAL AND ANTIBACTERIAL EFFICACY - Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The anti-microbial compositions contain (a) an antimicrobial agent, (b) a disinfecting alcohol, and (c) (i) an organic acid, (ii) an inorganic salt comprising a cation having a valence of 2, 3, or 4 and a counterion capable of lowering a surface pH to about 5 or less, (iii) an aluminum, zirconium, or aluminum-zirconium complex, or (iv) mixtures thereof, wherein the composition has a pH of about 5 or less. | 2012-11-01 |
20120276220 | Method of Treating Hepatitis - The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient. | 2012-11-01 |
20120276221 | BIODISINTEGRABLE MEDICAL DEVICES - According to an aspect of the present invention, the present invention provides medical devices which contain one or more polymeric regions that are at least partially biodisintegrable in bodily fluid. These devices may be implanted or inserted into a subject for treatment of various diseases, disorders and conditions. | 2012-11-01 |
20120276222 | Methods of using solutions of hypobromous acid and hypobromite to treat poultry in a chill tank during processing to increase the weight of the poultry - Methods for treating poultry to increase the weight of the poultry are disclosed. The methods may be performed in a chill tank or other reservoir and utilize hypobromous acid from either aqueous hydrogen bromide or aqueous sodium bromide and a source of hypochlorite. The methods comprise contacting a poultry carcass with the hypobromous acid-containing water at a pH of about 6.5 to about 10. The methods result in an increase in the weight of the processed poultry products. | 2012-11-01 |
20120276223 | COMPOSITION FOR PREVENTING AND TREATING INFLUENZA-VIRUS-INDUCED DISEASES - The present invention relates to a medicinal extract useful for preventing and treating influenza-virus-induced diseases, and to a pharmaceutical composition and health food including same. Derived from natural ingredients, the medicinal extract of the present invention is safe for humans, and can be used to prevent, treat, and alleviate symptoms of diseases induced by various strains of influenza viruses. | 2012-11-01 |
20120276224 | COMPOUND COMPRISING EXTRACTS OR FRACTIONS OF CHRYSANTHEMUM BOREALE MAKINO HAVING ANTI-INFLAMMATION ACTIVITY - The present invention relates to a composition having an anti-inflammatory activity, comprising extracts or fractions of | 2012-11-01 |
20120276225 | PHYTOESTROGENIC NUTRACEUTICAL COMPOSITION FROM PALM LEAF EXTRACT - A comestible composition with phytoestrogenic property against oxidative stress, retarding hormone related cancer, affecting fertility and effective to hinder or prevent ailments or conditions resulting from, or exacerbated by, a decrease in endogenous estrogen including: reproductive organ ailments, cardiovascular disease, osteoporosis, loss of cognitive function, urinary incontinence, body fat increase, post menopausal syndromes and vasomotor symptoms, and contains extract from palm leaf. | 2012-11-01 |
20120276226 | COMPOSITIONS COMPRISING EXTRACTS OF SOUTHERNWOOD AND AN AMINE COMPOUND - The present invention relates to compositions comprising a Southernwood extract and an amine compound, and methods treating skin with said compositions. | 2012-11-01 |
20120276227 | USE OF CAJEPUT AND PIMENTA RACEMOSA EXTRACT FOR TREATING PARASITIC INFESTATION OF FISH - The present invention relates to a combination of cajeput and extract from the plant | 2012-11-01 |